Tuberculosis (TB) prevention is essential for reaching the End TB targets in the South-East Asia Region (SEAR) of World Health Organization (WHO)1. The targets of 80% reduction in TB incidence rate and 90% reduction in TB mortality by 2030 (compared to 2015 levels) can be achieved only with addition...al interventions aimed at preventing TB, according to epidemiological modelling studies commissioned by the WHO South-East Asia Regional Office (WHO SEARO). Optimal implementation of TB preventive treatment (TPT) is a critical intervention to accelerate reduction in TB burden in the SEA Region, which bears nearly 43% of the global TB burden. TPT by itself has the potential to reduce the overall annual TB incidence rates by 8.3% (95% CrI 6.5–10.8) relative to 2015.
more
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...y of the most promising vaccine candidates among the region’s populations.
While current COVID-19 clinical trial activity on the continent is limited, Africa has substantial experience and capabilities to conduct clinical trials for preventative vaccines across a range of diseases, and many organizations on the continent are working tirelessly to help prepare additional trials on potential COVID-19 vaccines. As the number of candidate vaccines in the development pipeline continues to increase, it will be important for organizations responsible for managing clinical trials in the region to partner with vaccine developers to identify potential and appropriate trial locations, provide support to remove any critical obstacles impeding commencement and progress of trials, and to provide oversight ensuring that trials are conducted safely and ethically.
more
Calls for greater implementation research (IR) capacity came in the wake of compelling evidence that implementation strategies are critically important for the dissemination and facilitation of evidence-informed policies and interventions to tackle noncommunicable diseases (NCDs), thereby improving ...outcomes for both individuals and populations. However, at present, implementation of evidence-based interventions and policies is challenged by a gap in lack of academic research on how these cost–effective recommended interventions can be implemented in the context of local settings, especially those of low and middle-income.
more
Issue Brief no.8. January 18,2021
Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies,... implementation of the vaccination, ethical considerations, as well as educational materials in English and other languages.
more
Recommendations for health care professionals – the experience from Latvia
The Country Readiness and Delivery(CRD) workstream which is part of the ACT Accelerator and is included in the SPRP– has developed a toolbox with guidance, tools and training.
An Action Framework and annexe to Immunization Agenda 2030 (Draft version)
27 January 2021
This catalogue provides tools and information resources to support EU/EEA countries in addressing the challenging issue of vaccine hesitancy. The catalogue provides examples of practices that can serve as a resource for other countries. The project was developed in the context of ECDC’s support fo...r EU/EEA Member States in prevention and control of vaccine-preventable diseases, including effective communication to promote immunisation.
more
In its report from 2014, the Working Group outlines the various factors influencing vaccine acceptance or refusal, and what can be done to create social norms around vaccine acceptance and to encourage the general public regarding the necessity of vaccination.
Social and behavior change (SBC) professionals have often been tasked to find ways to influence knowledge, attitudes, and practices, about vaccines. Now that the COVID-19 vaccines are becoming available worldwide, renewed emphasis and urgency for SBC efforts arise.
To that end, WHO has offered thre...e factors that play a role in vaccine hesitancy, the first two of which can be addressed by SBC: Complacency: Low perceived risk of vaccine-preventable diseases, and vaccination not deemed necessary. Other life/health issues are a greater priority.
Confidence: Low levels of trust in vaccines, in the delivery system, and in health authorities
Convenience: Barriers related to geographic accessibility, availability, affordability, and acceptability of services
This resource page provide a selection of SBC research, tools, and examples that aid in understanding this issue, especially in light of the recent availability of COVID-19 vaccines and the urgency for immunization worldwide.
more
The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery workstream has released guidance on developing a national deployment and vaccination plan (NDVP) for COVID-19 vaccines. This course is intended to help national and sub-national focal points in countries develop the ND...VP and prepare for COVID-19 vaccine introduction.
Available in English and Macedonian
more
17 February 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Strategic communication is used to raise awareness of issues among specific target populations. It aims to provide timely, evidence-based, authoritative information and guidance needed for public health action. Proper implementation of strategic communication leads t...o sustained behaviour change and is essential in overcoming barriers to access to services or generating demand for such services.
more
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa